Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-02 By FDA
FDA Roundup: December 1, 2023
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-02 By FDA
ODACTRA
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-12-02 By FDA
Vaccines Licensed for Use in the United States
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-12-01 By FDA
Registered Outsourcing Facilities
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-01 By FDA
iPLEDGE Risk Evaluation and Mitigation Strategy (REMS)
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-01 By FDA
Novel Drug Approvals for 2022
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-01 By FDA
Drug Trials Snapshots
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-01 By FDA
Human medicines European public assessment report (EPAR): Orladeyo, berotralstat, Angioedemas, Hereditary, Date of authorisation: 30/04/2021, Revision: 5, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-01
Human medicines European public assessment report (EPAR): Semglee, insulin glargine, Diabetes Mellitus, Date of authorisation: 23/03/2018, Revision: 10, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-01
Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Stomach Neoplasms;Breast Neoplasms, Date of authorisation: 12/12/2018, Revision: 11, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-01
Human medicines European public assessment report (EPAR): Kirsty (previously Kixelle), insulin aspart, Diabetes Mellitus, Date of authorisation: 05/02/2021, Revision: 4, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-01
http://www.fda.gov/node
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-01 By FDA
Human medicines European public assessment report (EPAR): Hulio, adalimumab, Hidradenitis Suppurativa;Psoriasis;Uveitis;Arthritis, Rheumatoid;Spondylitis, Ankylosing;Crohn Disease;Colitis, Ulcerative;Arthritis, Psoriatic, Date of authorisation: 17/09/2018, Revision: 16, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-01
Questions and Answers on the iPLEDGE REMS
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-01 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.